UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)*

 

 

CytomX Therapeutics, Inc.

(Name of Issuer)

COMMON STOCK, $0.00001 PAR VALUE PER SHARE

(Title of Class of Securities)

23284F105

(CUSIP Number)

December 31, 2017

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

 

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

---

CUSIP No. 23284F105		SCHEDULE 13G		Page 2 of 12 Pages

 

1.		NAMES OF REPORTING PERSONS   Third Rock Ventures, L.P.
2.		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)  ☐        (b)  ☒
3.		SEC USE ONLY
4.		CITIZENSHIP OR PLACE OF ORGANIZATION   Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5.		SOLE VOTING POWER   0
				6.		SHARED VOTING POWER   3,320,348
				7.		SOLE DISPOSITIVE POWER   0
				8.		SHARED DISPOSITIVE POWER   3,320,348
9.		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   3,320,348
10.		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   ☐
11.		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9   8.6% (1)
12.		TYPE OF REPORTING PERSON   PN

 

(1)	The percent of class was calculated based on 38,408,626 shares of common stock issued and outstanding as of November 3, 2017, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 11, 2017.

---

CUSIP No. 23284F105		SCHEDULE 13G		Page 3 of 12 Pages

 

1.		NAMES OF REPORTING PERSONS   Third Rock Ventures GP, L.P.
2.		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)  ☐        (b)  ☒
3.		SEC USE ONLY
4.		CITIZENSHIP OR PLACE OF ORGANIZATION   Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5.		SOLE VOTING POWER   0
				6.		SHARED VOTING POWER   3,320,348
				7.		SOLE DISPOSITIVE POWER   0
				8.		SHARED DISPOSITIVE POWER   3,320,348
9.		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   3,320,348
10.		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   ☐
11.		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9   8.6% (1)
12.		TYPE OF REPORTING PERSON   PN

---

CUSIP No. 23284F105		SCHEDULE 13G		Page 4 of 12 Pages

 

1.		NAMES OF REPORTING PERSONS   TRV GP, LLC
2.		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)  ☐        (b)  ☒
3.		SEC USE ONLY
4.		CITIZENSHIP OR PLACE OF ORGANIZATION   Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5.		SOLE VOTING POWER   0
				6.		SHARED VOTING POWER   3,320,348
				7.		SOLE DISPOSITIVE POWER   0
				8.		SHARED DISPOSITIVE POWER   3,320,348
9.		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   3,320,348
10.		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   ☐
11.		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9   8.6% (1)
12.		TYPE OF REPORTING PERSON   OO

---

CUSIP No. 23284F105		SCHEDULE 13G		Page 5 of 12 Pages

 

1.		NAMES OF REPORTING PERSONS   Mark Levin
2.		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)  ☐        (b)  ☒
3.		SEC USE ONLY
4.		CITIZENSHIP OR PLACE OF ORGANIZATION   United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5.		SOLE VOTING POWER   145,286
				6.		SHARED VOTING POWER   3,320,348
				7.		SOLE DISPOSITIVE POWER   145,286
				8.		SHARED DISPOSITIVE POWER   3,320,348
9.		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   3,465,634
10.		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   ☐
11.		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9   9.0% (1)
12.		TYPE OF REPORTING PERSON   IN

---

CUSIP No. 23284F105		SCHEDULE 13G		Page 6 of 12 Pages

 

1.		NAMES OF REPORTING PERSONS   Kevin P. Starr
2.		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)  ☐        (b)  ☒
3.		SEC USE ONLY
4.		CITIZENSHIP OR PLACE OF ORGANIZATION   United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5.		SOLE VOTING POWER   0
				6.		SHARED VOTING POWER   3,320,348
				7.		SOLE DISPOSITIVE POWER   0
				8.		SHARED DISPOSITIVE POWER   3,320,348
9.		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   3,320,348
10.		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   ☐
11.		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9   8.6% (1)
12.		TYPE OF REPORTING PERSON   IN

---

CUSIP No. 23284F105		SCHEDULE 13G		Page 7 of 12 Pages

 

1.		NAMES OF REPORTING PERSONS   Robert I. Tepper
2.		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)  ☐        (b)  ☒
3.		SEC USE ONLY
4.		CITIZENSHIP OR PLACE OF ORGANIZATION   United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5.		SOLE VOTING POWER   85,509
				6.		SHARED VOTING POWER   3,320,348
				7.		SOLE DISPOSITIVE POWER   85,509
				8.		SHARED DISPOSITIVE POWER   3,320,348
9.		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   3,405,857
10.		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   ☐
11.		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9   8.9% (1)
12.		TYPE OF REPORTING PERSON   IN

---

CUSIP No. 23284F105		SCHEDULE 13G		Page 8 of 12 Pages

 

Item 1.

Issuer

 

(a)

Name of Issuer:

CytomX Therapeutics, Inc. (the “Issuer”)

 

(b)

Address of Issuer’s Principal Executive Offices:

151 Oyster Point Blvd, Suite 400

South San Francisco, CA 94080

 

Item 2.

Filing Person

 

(a) – (c)

Name of Persons Filing; Address; Citizenship:

 

(i)

Third Rock Ventures, L.P. (“TRV”);

 

(ii)

Third Rock Ventures GP, L.P. (“TRV GP”), which is the sole general partner of TRV;

 

(iii)

TRV GP, LLC (“TRV GP LLC”), which is the sole general partner of TRV GP;

 

(iv)

Mark Levin (“Levin”), a managing member of TRV GP LLC;

 

(v)

Kevin P. Starr (“Starr”), a managing member of TRV GP LLC; and

 

(vi)

Robert I. Tepper (“Tepper,” and collectively with TRV, TRV GP, TRV GP LLC, Levin and Starr, the “Reporting Persons”), a managing member of TRV GP LLC.

The address of the principal business office of each of the Reporting Persons is Third Rock Ventures, LLC, 29 Newbury Street, 3rd Floor, Boston, MA 02116.

Each of TRV and TRV GP is a Delaware limited partnership. TRV GP LLC is a Delaware limited liability company. Levin, Tepper, and Starr are United States citizens.

 

(d)

Title of Class of Securities:

Common stock, $0.00001 par value per share, (the “Common Stock”).

 

(e)

CUSIP Number:

23284F105

 

Item 3.

If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

 

---

CUSIP No. 23284F105		SCHEDULE 13G		Page 9 of 12 Pages

 

If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

 

Item 4.

Ownership.

 

(a) and (b)

Amount beneficially owned:

 

(i)

TRV directly owns 3,320,348 shares of Common Stock (the “Shares”), which represents approximately 8.6% of the outstanding shares of Common Stock.

 

(ii)

TRV GP is the general partner of TRV and may be deemed to beneficially own the Shares.

 

(iii)

TRV GP LLC is the general partner of TRV GP and may be deemed to beneficially own the Shares.

 

(iv)

As a managing member of TRV GP LLC, Levin may be deemed to beneficially own the Shares. Additionally, as of December 31, 2017, Levin directly owns 145,286 shares of Common Stock. As a result, Levin may be deemed to beneficially own an aggregate of 3,465,634 shares of Common Stock, which represents approximately 9.0% of the outstanding shares of Common Stock.

 

(v)

As a managing member of TRV GP LLC, Tepper may be deemed to beneficially own the Shares. Additionally, as of December 31, 2017, Tepper directly owns 85,509 shares of Common Stock. As a result, Tepper may be deemed to beneficially own an aggregate of 3,405,857 shares of Common Stock, which represents approximately 8.9% of the outstanding shares of Common Stock.

 

(vi)

As a managing member of TRV GP LLC, Starr may be deemed to beneficially own the Shares.

 

(c)

Number of shares as to which such person has:

 

		Number of Shares of Common Stock
Reporting Person		(i)				(ii)				(iii)				(iv)
TRV							3,320,348								3,320,348
TRV GP							3,320,348								3,320,348
TRV GP LLC							3,320,348								3,320,348
Levin			145,286				3,320,348				145,286				3,320,348
Starr							3,320,348								3,320,348
Tepper			85,509				3,320,348				85,509				3,320,348

 

(i)	Sole power to vote or direct the vote

(ii)	Shared power to vote or to direct the vote

(iii)

Sole power to dispose or to direct the disposition of

(iv)	Shared power to dispose or to direct the disposition of

---

CUSIP No. 23284F105		SCHEDULE 13G		Page 10 of 12 Pages

 

The percent of class was calculated based on 38,408,626 shares of common stock issued and outstanding as of November 3, 2017, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 11, 2017.

 

Item 5.

Ownership of Five Percent or Less of a Class.

Not applicable.

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

 

Item 8.

Identification and Classification of Members of the Group.

Not applicable.

 

Item 9.

Notice of Dissolution of Group.

Not applicable.

 

Item 10.

Certification.

Not applicable.

---

CUSIP No. 23284F105		SCHEDULE 13G		Page 11 of 12 Pages

 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 13, 2018

 

---

CUSIP No. 23284F105		SCHEDULE 13G		Page 12 of 12 Pages

 

---

EXHIBIT 24

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Kevin Gillis his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a direct or indirect general partner, director, officer, member or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his substitutes, may lawfully do or cause to be done by virtue hereof. Each of the undersigned may execute this power of attorney in separate counterparts, and each counterpart shall be deemed to be an original instrument. This agreement shall be effective as to each of the undersigned as of the date signed by that signatory.

IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 16th day of January, 2014.

 

---

EXHIBIT 99.1

Joint Filing Agreement

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

Dated: February 13, 2018

 

---